Clinical TrialMay 18, 2026, 07:02 AM
BeyondSpring to Present Plinabulin Phase 2 NSCLC Data at ASCO 2026
AI Summary
BeyondSpring Inc. announced an upcoming poster presentation of its investigator-initiated Study 303 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 2 study evaluates Plinabulin, Docetaxel, and Pembrolizumab in 47 patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on PD-1/PD-L1 inhibitors. The presentation will cover the efficacy and immunophenotyping of this triple combination therapy.
Key Highlights
- BeyondSpring to present Study 303 data at the 2026 ASCO Annual Meeting.
- Study 303 is a Phase 2 trial of Plinabulin/Docetaxel/Pembrolizumab.
- The study enrolled 47 patients with 2L/3L metastatic NSCLC.
- Presentation scheduled for May 31, 2026, 9:00 a.m. to 12:00 p.m. CDT.
- Primary endpoint is investigator-based ORR (RECIST 1.1).
- Study 303 is supported by Merck and BeyondSpring.
Price Impact
More from BYSI